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Abstract
Maternal infection is a common occurrence during pregnancy, with a substantial 
impact on the infant. Some infections result in impaired development in utero and 
even death of the fetus. Other infections may be insidious in the mother but result 
in growth impairment and hearing loss in the infant. A growing body of evidence 
suggests that even infections such as chorioamnionitis, thought to have no long-
term impact on the infant, may alter fetal development. This chapter will review 
congenital infections and their impact on neonatal outcomes, as well as newer 
findings suggesting that acute infection may result in adverse changes in the infant. 
We will explore novel mechanisms of pathogenesis and virulence, as well as areas 
that continue with ongoing research.
Keywords: pregnancy, infection, neurodevelopment, chorioamnionitis, TORCH 
infections, Zika
1. Introduction
Maternal infections during pregnancy can have a direct impact on the devel-
oping fetus and in some infections can result in fetal demise. It is extremely 
important to screen women for infections when it is available and practical 
and to treat when necessary. The current screening tests recommended by the 
American College of Obstetricians and Gynecologists include rubella, hepatitis 
B, hepatitis C, human immunodeficiency virus (HIV), Group B streptococcus 
(GBS), tuberculosis and sexually transmitted infections including syphilis, 
chlamydia, and gonorrhea if risk factors are present [1]. The incidence of 
congenital infections in infants varies, with syphilis increasing dramatically 
from 639 cases in 2016 to over 1300 cases in 2018 in the United States [2]. 
Additionally, congenital cytomegalovirus, varicella zoster virus and herpes 
simplex virus diagnoses have increased over the last five decades [3]. Rubella 
has decreased since the introduction of Rubella immunization; prior to utiliza-
tion of the immunization, over 100,000 infants were born worldwide with 
congenital rubella syndrome (CRS). By 2014, a 95% decrease in cases of CRS 
was observed in countries that followed the immunization schedule [4]. Thus, 
it is critically important that research efforts continue to prioritize the develop-
ment of immunizations and treatments plans for all viruses that can result in 
congenital fetal infection in an attempt to minimize the substantial long-term 
morbidities that result.
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2. Chorioamnionitis/intra-amniotic infection (IAI)
Chorioamnionitis is the term that has been used for decades to describe infection 
and/or inflammation of the chorion, amnion, or both. This has been further delin-
eated into a “clinical” diagnosis based on maternal symptoms, and a “histological” 
diagnosis based on the pathology of the placenta following delivery. Clinical signs 
and symptoms are used to diagnose clinical chorioamnionitis, and include maternal 
fever, uterine fundal tenderness, maternal and/or fetal tachycardia and purulent 
amniotic fluid [5]. The most common bacterial organisms to cause chorioamnionitis 
are Ureaplasma urealyticum and Mycoplasma hominis. Histological chorioamnionitis 
is diagnosed by observing neutrophil infiltration into the chorion and amnion 
[6]. The variation in the definition of chorioamnionitis has resulted in confusion 
in neonatal management as well as difficulty in assessing the long-term impact of 
chorioamnionitis on development. Therefore, intra-amniotic infection (IAI) has 
been developed to replace the prior diagnosis of chorioamnionitis [7].
IAI was updated in 2017 by the American College of Obstetricians and 
Gynecologists into three categories which are readily diagnosed. Isolated maternal 
fever (IMF) is the first category, in which the mother has a single intrapartum 
temperature of ≥39.0°C or a temperature of 38.0–38.9°C that persists for 30 min, 
with treatment recommendations including the consideration of broad-spectrum 
antibiotics [7, 8]. Given the numerous potential causes of maternal fever, the 
utilization of antibiotics is at the providers’ discretion. Suspected IAI is diagnosed 
when the mother has an elevated temperature (≥39.0°C) or a slightly elevated 
temperature (38.0–38.9°C) along with one of the following risk factors: maternal 
leukocytosis, purulent cervical drainage or fetal tachycardia [7, 8]. Confirmed IAI 
is diagnosed with a positive amniotic fluid test or placental pathology demonstrat-
ing histologic evidence of infection [7]. Similar to the previously used histological 
chorioamnionitis, a criticism of this diagnosis is that it is made after the clinical 
situation has resolved, and thus does not aid in the acute management of the mother 
or the infant. Both suspected and confirmed IAI diagnoses should result in treat-
ment with intrapartum antibiotics and antipyretics [7].
IAI is present in nearly 50% of very early preterm birth [9], after which 
multiple complications can occur and a wide array of neonatal morbidities and 
mortalities are observed. This has led to speculation that IAI is directly impacting 
the fetal and neonatal development and outcomes, as well as potentially resulting 
in preterm birth, which then impacts development and outcomes. The majority 
of studies that have investigated this question utilized diagnoses of chorioamnio-
nitis, which included both clinical and histological cases. Given the variation of 
diagnoses included in these studies, it is not surprising that the results have also 
been varied. A large study of 2390 extremely preterm infants (born <27 weeks’ 
gestational age) from sixteen centers across the United States found infants 
exposed to histological and clinical chorioamnionitis had an increased risk of 
cognitive impairment at 18–22 months’ corrected age [10]. A separate study of 
350 infants found that while gestational age was significantly lower among those 
with exposure to histological chorioamnionitis, there was no association with 
intraventricular hemorrhage, white matter injury around birth, or differences 
in cognitive or motor outcomes at 18–24 months’ corrected age [11]. Additional 
studies have found weak causal or associative roles of chorioamnionitis with 
cerebral palsy risk [12] and no increased risk of white matter injury on magnetic 
resonance imaging (MRI) following histological chorioamnionitis in premature 
infants [13]. Additional investigation is required with the new IAI definitions to 
determine if there are consistent findings with developmental outcomes in those 
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3. TORCH infections
TORCH infection is a mnemonic that has classically been used to describe 
congenital infections that can impact fetal development. In the past, TORCH 
represented Toxoplasmosis, Other (syphilis, varicella-zoster, parvovirus B19 and 
newer pathogens such as Zika), Rubella, Cytomegalovirus and Herpes Simplex 
Virus. However, as more pathogens are being discovered and the “other” category is 
expanding, some experts feel the mnemonic is not as relevant today.
3.1 Toxoplasmosis
Toxoplasma gondii is an obligate intracellular protozoan which typically causes 
mild illness in most immunocompetent individuals [14, 15]. While a large portion 
of infected children and adults are asymptomatic, Toxoplasmosis is considered one 
of the major causes of death linked to foodborne illness in the United States. If an 
immunocompromised individual, pregnant woman, or fetus/infant acquires the 
infection, there can be severe, even fatal, consequences [14, 15]. Illness can range 
from non-specific systemic symptoms such as fever, lymphadenopathy and hepato-
splenomegaly to congenital toxoplasmosis (CT), which is classically described as a 
triad of chorioretinitis, intracranial calcifications and hydrocephalus. CT can lead 
to loss of vision and hearing, decreased cognitive function, and neurodevelopmen-
tal delay if untreated [14, 16–18].
T. gondii exists in three forms: tachyzoite, bradyzoite, and sporozoite. The 
definitive hosts are members of the Felidae family, but warm-blood mammals 
can also serve as intermediate hosts [17]. Felines can acquire T. gondii through the 
ingestion of tissue cysts containing bradyzoites in infected prey or through the 
ingestion of oocysts containing sporozoites in anything contaminated with feces 
from an infected cat. They can excrete un-sporulated oocysts in their stools 3–30 
days after infection and can shed for 7–14 days. If in the right climate (such as 
warm and humid), the oocysts can sporulate for 1–5 days, after which they can 
remain infectious for years. If the tissue cysts found in intermediate hosts or the 
sporulated oocysts are ingested by humans, they transform into active tachyzoites. 
The tachyzoites then primarily infect the central nervous system, eyes, musculo-
skeletal system, and placenta by infecting nucleated host cells to bypass the blood 
brain barrier and placental barricade. Incubation is 7 days with a range of 4–21 days 
[14, 15, 18].
For pregnant women who have an acute infection with T. gondii, the timing 
can be crucial and dictates the treatment course. Typically, the earlier in preg-
nancy that acute infection occurs, the lower the rate of transmission to the fetus. 
Unfortunately, there is an increased severity of illness if transmission occurs earlier 
in the pregnancy [14, 15]. The reverse is true for infection later in pregnancy (such 
as during the third trimester), during which there is a high rate of transmission but 
with less severe illness in the fetus.
The diagnosis of primary or latent infection is made primarily using serologic 
tests. Toxoplasma-specific Immunoglobulin G (IgG) and Immunoglobulin M 
(IgM) can be performed routinely at non-reference laboratories. Any positive IgM 
results are then submitted to reference laboratories that can perform additional 
testing for confirmation [18]. If a pregnant woman is found to have acute infection, 
then an amniocentesis can be performed, and the fluid can be sent for polymerase 
chain reaction (PCR) testing. If the PCR is negative and the fetus is believed to 
have not acquired the infection, the next best step is treatment in the mother with 
spiramycin in an attempt to prevent transmission [14, 15, 17, 18]. If, however, the 
fetus is thought to be infected, then the mother is started on a combination of 
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pyrimethamine, sulfadiazine, and folinic acid. Spiramycin, a primarily bacterio-
static macrolide that has activity against some gram-negative and gram-positive 
organisms as well as some spirochetes, is unable to cross the placenta whereas the 
combination of anti-parasitic medications can cross the placenta and thus can aide 
in treatment of the fetus [18, 19]. The combination is also used for fetal infection 
confirmed at or after 18 weeks of gestation or maternal infection acquired during 
the third trimester [14, 17, 18]. As untreated CT can lead to fetal demise or death 
within the first few days of life, and chorioretinitis can develop in a significant 
proportion of infants whose mothers were untreated, it is imperative to diagnose 
and start treatment in a timely manner [18].
Once an infant with suspected CT is born, he or she should be thoroughly 
examined and evaluated. Serologies, a complete blood count (CBC), hepatic 
function tests, blood PCR, urine PCR, cerebrospinal fluid (CSF) PCR, and CSF 
studies including glucose level, protein, and cell count, should be sent [18]. The 
newborn should also have ophthalmologic, auditory, and neurologic evaluation 
including imaging of the brain [18]. Infected infants should receive treatment 
regardless of any clinically apparent symptoms, as a large proportion of infants 
with asymptomatic CT at birth go on to develop visual/hearing impairment, 
learning disabilities, and psychomotor delay [15, 16, 18, 20]. Treatment consists of 
the same anti-parasitic combination of pyrimethamine, sulfadiazine, and folinic 
acid [18, 19]. If CSF studies show an elevated protein concentration (greater than 
1 g/dL) or there is evidence of severe chorioretinitis, then a corticosteroid such as 
prednisone is added until there is a decrease in protein concentration in the CSF 
or resolution of severe chorioretinitis [15, 18, 19]. Treatment is continued at least 
though 12 months of age, with consideration of shorter treatment duration for 
infants who remain asymptomatic for the first three months of life [18, 19]. For 
those infants who are asymptomatic with positive Toxo-specific IgG but negative 
IgM and Immunoglobulin A (IgA), there should be repeat IgG testing every four to 
six weeks until disappearance of IgG. There is no clear consensus on the treatment 
of these infants [18, 19].
Studies looking at the outcomes of infants with CT have shown significantly 
better neurologic and developmental outcomes in those that were treated than 
those who were not [21]. It is important to note that compared to their uninfected 
siblings, the children that received treatment had a lower level of cognitive function 
though there was no deterioration over time. In terms of ophthalmologic outcomes, 
it was found that when followed up to 22 years of age, new ocular lesions could be 
detected in adolescence which points to the importance of continued ophthalmo-
logic evaluation.
3.2 Other: syphilis, varicella-zoster, parvovirus B19, Zika
3.2.1 Syphilis
Treponema pallidum, a thin, motile spirochete, is the organism that causes syphi-
lis [18], a sexually transmitted infection that can also result in congenital infection 
to a fetus. While there was initially a decline in the cases of syphilis observed in the 
United States in 2000–2001, an alarming resurgence has recently been noted. There 
has been an increase of 72% in the number of reported primary and secondary 
cases in the United States from 2013 to 2017, with the number of congenital syphilis 
cases increasing more than 150% from 2013 to 2018 [22–24]. It is thought that the 
increase in methamphetamine use, having sex with a person who injects drugs, 
injection drug use and heroin use are the primary factors that are leading to this 
dramatic increase in syphilis cases [22, 25].
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Acquired syphilis is typically divided into three stages: primary, secondary and 
latent. During the primary stage, painless indurated ulcers form on the skin or 
mucous membranes of the areas exposed and heal spontaneously in a few weeks. 
The secondary stage, typically 1–2 months after the primary stage, is characterized 
by a maculopapular rash that typically includes the palms and soles, lymphade-
nopathy and mucocutaneous lesions including condylomata lata [18]. Finally, the 
latent stage occurs when there are no clinical signs or symptoms of infection, but 
an individual remains seroreactive [18]. T. pallidum can infect the central nervous 
system (CNS) during any stage, resulting in neurosyphilis. Transmission to the 
fetus during pregnancy can occur at any point, with primary and secondary syphilis 
having the highest rates of transmission at 60–100% [18].
It is recommended that all women be screened for syphilis early in pregnancy 
with a nontreponemal test, with repeat testing later in pregnancy for high risk indi-
viduals. These tests include the Venereal Disease Research Laboratory (VDRL) slide 
test and the rapid plasma reagin (RPR) test [18]. These nontreponemal tests utilize 
an antigen that reacts in the presence of antibodies (to syphilis). However, given 
that the antigen is not specific for syphilis and is a component of cell membranes, 
false positives may result from other infections including varicella and measles, or 
by tissue damage observed in connective tissue disease and even pregnancy itself 
[26]. Therefore, a positive nontreponemal test should be followed by a confirmatory 
test such as fluorescent treponemal antibody absorption (FTA-ABS) or T. pallidum 
particle agglutination (TP-PA) tests. Additionally, any person found positive for 
syphilis based on screening and confirmatory testing should also be screened for 
human immunodeficiency virus (HIV) given the high rate of co-infection.
Treatment for syphilis is parenteral penicillin G; if an individual is allergic to 
penicillin G, they should undergo desensitization due to the lack of proven efficacy 
of alternative agents in this setting. Lack of treatment during pregnancy can result 
in stillbirth and neonatal death in nearly 40% of women with primary and second-
ary stage disease, 40% of infants being infected and only 20% of infants being 
healthy and uninfected [27]. Additionally, fetal infection can result in anemia, 
hepatomegaly and hydrops [24]. Treatment of the infant should not be delayed, as 
early treatment may prevent neurologic sequelae [24].
A serological diagnosis is made on the infant if the nontreponemal titer (VDRL 
or RPR) is fourfold higher than that of the mother (both samples should be 
obtained around the same time), if the nontreponemal titer persists or increases 
after birth, or if the treponemal antibody titer (FTA-ABS or TP-PA) remains posi-
tive at 12–18 months of age. The choice of test on the infant is dependent on the test 
that the mother had received, as the titers will need to be compared [18]. A com-
plete evaluation, including complete blood cell count (CBC), liver function tests, 
obtaining cerebrospinal fluid (CSF) to test for VDRL reactivity, ophthalmologic 
examination and long-bone radiographs to assess abnormal ossification, radiolu-
cencies or dislocation of epiphyses is then needed [28]. Neuroimaging should be 
considered if there are any concerns for central nervous system involvement [18]. 
Ten days of treatment with parenteral penicillin G is typically used in infected 
infants, with close follow up required. Titers should be repeated by 3 months of 
age and noted to be declining, with nonreactivity noted by 6 months of age [28]. If 
the mother received appropriate treatment that was administered >4 weeks before 
delivery, and the infant has a normal physical examination with the titer equal to or 
less than fourfold the maternal titer, then no evaluation is recommended. However, 
inadequate treatment in the mother should result in evaluation of the infant and 
treatment with penicillin G for 10 days [28].
Clinically, nearly half of infants do not have any apparent signs of infection, 
although bone lesions and hematologic and hepatobiliary abnormalities may be 
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present, with hepatomegaly one of the most common findings [24, 29]. Infants that 
develop symptoms may have rhinitis in the first week of life, in which persistent 
white discharge (“snuffles”) occurs which contains spirochetes [29]. Additional 
symptoms can include generalized lymphadenopathy and a maculopapular rash 
[29]. Long term outcomes of infants not appropriately treated can include senso-
rineural hearing loss, interstitial keratitis, secondary glaucoma, corneal scarring, 
vision impairment, Hutchinson teeth (smaller teeth that are widely spaced with 
notches), saber shins (sharp anterior bowing of the tibia), frontal bossing, saddle 
nose, gummas (soft, non-cancerous growth) and scarring [29]. Life-long dis-
abilities can occur in congenital syphilis infections if infants are not appropriately 
screened and treated [28].
3.2.2 Varicella-zoster
Varicella-zoster virus (VZV) is a herpesvirus that is transmitted by respiratory 
droplets, direct contact with skin lesions, and transplacentally during pregnancy 
[30]. Infants that are exposed to VZV during the last few weeks of pregnancy may 
develop neonatal varicella which can be quite severe; congenital varicella syndrome 
(CVS) develops in infants exposed during the pregnancy, with the risk being high-
est if the exposure occurs in the first trimester [30]. Infants exposed after 20 weeks’ 
gestation only have about 2% chance of developing CVS [31]. Infants with CVS 
most commonly have skin lesions in a dermatomal distribution followed by neuro-
logic defects, eye disease and skeletal anomalies [31]. Neurologic defects can include 
cerebral cortical atrophy and ventriculomegaly. Unfortunately, CVS is fatal in about 
30% of cases within the first month of life [32].
The monovalent vaccine approved in 1995 and the quadrivalent vaccine intro-
duced in 2005 have impacted the prevalence of congenital infection as seroprotec-
tion is nearly 100% after 2 doses of the vaccine [18]. Thus, at this time, CVS is 
considered an extremely rare disorder.
3.2.3 Parvovirus B19
Human parvovirus B19 is a nonenveloped, single-stranded deoxyribonucleic 
acid (DNA) virus with humans as the only host [18]. The virus replicates in eryth-
rocyte precursors and is transmitted via respiratory tract secretions, exposure to 
blood or blood products, and vertically [18]. While it often causes a mild respira-
tory tract infection with a “slapped cheek” rash, it can be lethal to a fetus, with the 
risk of death being as high as 10% [33]. The incidence of parvovirus B19 infection 
during pregnancy is 3–4%, with the transplacental transmission rate approaching 
30% [34]. Fortunately, approximately 50–75% of women of reproductive age are 
immune to parvovirus B19 [35]. The timing of infection during pregnancy does 
alter the risk of fetal death, with first trimester infections resulting in up to 71% risk 
of fetal loss [34]. The difficulty in diagnosing the virus during pregnancy arises in 
the lack of symptoms that most adults experience, and as many as 70% of women 
would have no symptoms if infected during pregnancy [34]. Arthropathies are one 
of the most common symptoms and should raise suspicion for possible infection 
[34]. Additionally, the presence of fetal ascites or pericardial effusions on ultra-
sound should trigger high suspicion as well [33].
Fetal hydrops, or abnormal accumulation of fluid/edema in two or more 
compartments, is common in the setting of Parvovirus B19 infection, with a meta-
analysis finding a 9.3% pooled incidence, as well as an increased risk of fetal loss, 
spontaneous abortion and stillbirth [36]. Parvovirus B19 is among the most common 
causes of non-immune fetal hydrops, and while spontaneous resolution of infection 
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can occur, only about 5% of cases with hydrops will show spontaneous resolution of 
the infection with disappearance of hydrops on follow up ultrasounds [37].
Severe anemia and thrombocytopenia occur in utero following parvovirus B19 
infection, along with myocardial dysfunction [38]. These factors together are likely 
the etiology of the fetal hydrops. In utero transfusions (IUT) are often necessary 
and reduce mortality rates when compared to expectant management. A meta-
analysis found IUT was performed in 78% of hydropic fetuses compared to 29% 
of non-hydropic fetuses, with the difference likely due to the hydropic fetuses at 
higher risk of demise [37]. Complications may occur in up to 5% of cases, especially 
if the fetus is likely more sensitive to vascular overload [38]. Thus, intrauterine 
exchange transfusions (IUET) have also been attempted in cases of fetal hydrops in 
the setting of parvovirus B19 infection. Unfortunately, thus far it results in similar 
survival rates as IUT and does not seem to be clinically superior as a treatment 
modality [38].
Longer-term testing reveal abnormal neurodevelopment following intrauterine 
parvovirus B19 infections in those also diagnosed with hydrops. Brain abnormalities 
including parenchymal calcifications, venous infarction, arterial infarction, cer-
ebellar hemorrhage, and cortical malformations including diffuse cortical dysplasia 
and polymicrogyria have been described in congenital parvovirus infections [39]. 
If there are no abnormalities on imaging and hydrops resolves prior to delivery, one 
study found normal neurodevelopment in survivors at 1- and 5-year follow-up [40]. 
While the overall risk of mortality and morbidity are high, there is the potential for 
a normal outcome in select cases of congenital parvovirus infections.
3.2.4 Zika
Zika virus, ZIKV, is an emerging flavivirus that first became apparent interna-
tionally after Brazil declared a national public health emergency in 2016 followed 
by the World Health Organization declaring the outbreak a public health event of 
international concern [41]. The virus was first identified in 1947 in Uganda, after 
which cases of human infection have been infrequent and fairly localized [41]. 
ZIKV is transmitted by infected Aedes spp. mosquitoes, sexual contact and blood 
transfusions [42]. Around 80% of ZIKV that occur in adults are asymptomatic, 
with other cases having a mild febrile illness, headache, rash, fever and conjunctivi-
tis [42]. However, severe neurologic sequalae can also occur in adults.
Congenital Zika syndrome (CZS) is variable in the presentation and severity 
with only a subset of infants that were exposed having apparent signs and symp-
toms at birth [41]. Infants exposed to ZIKV in utero are expected to survive, how-
ever a severe phenotype can result, particularly when exposure occurs in the first 
trimester [43]. ZIKV replication in brain tissue can continue after birth, and thus 
infants that are initially asymptomatic may develop symptoms within the first year 
of life [41]. The phenotype of CZS appears to consist of severe microcephaly and 
possibly a partially collapsed skull, thin cerebral cortices with subcortical calcifica-
tions, macular scarring, congenital contractures and marked early hypertonia [41]. 
Microcephaly is the most common symptom, occurring in up to 91% of CZS, and is 
often severe with the mean occipitofrontal head circumference falling 3–4 standard 
deviations below normal [43]. Both the central and peripheral nervous systems are 
impacted, with resultant effects on musculoskeletal, auditory and ophthalmologic 
systems and symptoms including conductive hip dysplasia, abnormal posturing 
of extremities, conductive hearing loss and abnormalities of the retina and optic 
nerve [43]. Up to 55% of infants with CZS have structural ocular abnormalities, 
making visual screening and interventions critically important to occur early in 
life to allow for neuroplasticity optimizing the outcomes [44]. This has led to the 
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recommendation of any infant with suspected CZS or exposure to ZIKV to have an 
ocular examination before hospital discharge and again at 3 months of age [44].
A meta-analysis of 42 articles revealed the most common brain abnormalities 
following ZIKV exposure in utero, including decreased brain volume, increased 
extra-axial cerebrospinal fluid space, subcortical calcifications, microcephaly, 
ventriculomegaly, malformation of cortical development, basal ganglia calcifica-
tions, and mega cisterna magna [45]. These findings support the concept that ZIKV 
interferes with normal neuronal migration during development which then impacts 
the brain development. The major neuronal migration is occurring before the 25th 
week of gestation, making exposure to the virus in the first and second trimesters 
the most devastating. Infants with ZIKV exposure and no apparent congenital 
syndrome are also at risk for abnormal neurodevelopmental outcomes, as evidenced 
in a recent study of 70 infants followed to age 18 months [46]. These infants had 
confirmed exposure to ZIKV but no findings to support CZS, and despite the nor-
mal head circumference, had subsequent neurodevelopmental deficits develop over 
the first year of life [46]. As studies continue and longer-term outcomes become 
known, it is critically important to follow any infant with ZIKV exposure closely.
3.3 Rubella
Rubella is caused by a single stranded ribonucleic acid (RNA) virus which is 
highly contagious and only transmitted between humans [18, 47]. It is usually 
spread through respiratory droplets and in most cases will result in a mild viral dis-
ease. Symptoms may include fever, rash, malaise and adenopathy. The virus is able 
to infect cells of the respiratory tract and then spread via the systemic circulation 
to multiple organ systems, including the placenta [48]. When the infection occurs 
during pregnancy the virus can be transmitted to the fetus and result in death of the 
fetus or a range of congenital anomalies known collectively as Congenital Rubella 
Syndrome (CRS) [18]. The timing of when a pregnant woman contracts the virus 
appears to be related to the risk of congenital infection and fetal defects. Studies 
estimate that maternal infection occurring during the first 12 weeks of gestation has 
roughly a 90% chance of congenital infection with the risk of defects nearly 85% 
[49]. When congenital infection occurs during the first trimester, hearing defects, 
heart defects, neurologic damage, and ocular defects appear more commonly. 
CRS is a combination of these defects but most classically is described as a triad 
of cataracts, congenital heart disease, and sensorineural deafness [49, 50]. Other 
manifestations include intrauterine growth restriction (IUGR), hepatomegaly, 
splenomegaly, thrombocytopenia and dermal erythropoiesis (commonly known as 
a “blueberry muffin rash”) [18].
Pregnant women in the United States are tested for rubella immunity by sero-
logic screening. Those who have had a natural infection or have received at least one 
dose of the rubella vaccine tend to have lifelong immunity [18]. Those women who 
are found to be non-immune should receive one dose of the vaccine after childbirth, 
as vaccination during pregnancy has theoretical teratogenic risks due to the vaccine 
being live [18]. If a pregnant woman is exposed to the rubella virus, they should 
have serologic testing for rubella-specific IgM and IgG. If she is found to have 
rubella-specific IgG, then she is considered immune. However, if there is no IgG 
detectable at the time of exposure then convalescent serologies are obtained 3 and 
6 weeks after exposure, with IgG reactivity at these time points indicating a recent 
infection [18]. Unfortunately, there is no treatment for rubella outside of supportive 
measures.
When congenital infection is suspected, diagnosis can be done by testing for 
rubella-specific IgM in fetal blood or detection of the virus in amniotic fluid [49]. 
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Postnatally, an enzyme-linked immunosorbent assay (ELISA) can also be done 
for rubella-specific IgM. If positive, then confirmatory testing is done by reverse 
transcription polymerase chain reaction (RT-PCR) of nasopharyngeal swabs, urine, 
or oral fluid [47, 49]. In some infants the virus can be detected in nasopharyngeal 
secretions and urine for over a year [18, 49]. While there is no treatment for CRS, 
diagnosis is important in terms of follow up. Due to the risk of cataracts among 
other ocular abnormalities (including microphthalmia, glaucoma, chorioretinitis), 
hearing loss, neurologic manifestations (such as developmental delay, autism), and 
endocrine disorders (including diabetes, thyroid disease) children with CRS must 
be evaluated periodically for management of these potential complications [48–50]. 
The introduction of the vaccine has resulted in a significant decline in cases of 
rubella infection and CRS in the United States, with an average of 14 reported 
rubella cases a year and 4 CRS cases a year from 2001 to 2004 [51].
3.4 Cytomegalovirus
Cytomegalovirus (CMV) is a double stranded deoxyribonucleic acid (DNA) 
virus that is universally found and generally causes mild or subclinical symptoms 
in most children and adults [18, 52]. It can be transmitted via contact with infected 
secretions, transfusion of blood products from infected donors, organ transplants 
from infected individuals, or vertically [18]. When it is vertically transmitted, 
CMV has the potential to cause severe and permanent sequelae [18, 52, 53]. CMV 
is known as one of the most common congenital viral infections and is the leading, 
non-genetic cause of sensorineural hearing loss in children in the United States 
[18]. It can be transmitted to the fetus by crossing the placenta, through contact 
of infected cervical secretions during birth, or perinatally by ingestion of breast 
milk containing the virus [18]. When CMV is transmitted in utero, it can be due to 
primary maternal infection during pregnancy, reactivation of a prior infection, or 
reinfection with a different strain despite presence of maternal antibodies [54, 55]. 
Reactivation and reinfection are more common than a primary infection; however, 
the latter tends to cause more severe sequelae especially if infection occurs earlier in 
pregnancy.
Of those infants whose mother had an acute infection during pregnancy, 
30–40% will have congenital CMV (cCMV) [18, 55]. Infants with cCMV are symp-
tomatic in 10–15% of the cases, with half to two-thirds of these infants developing 
sensorineural hearing loss (SNHL) later in life [55]. Symptoms at birth can include 
thrombocytopenia, hepatomegaly, splenomegaly, microcephaly, periventricular 
calcifications in the brain, chorioretinitis, hepatitis, and SNHL. Long term out-
comes include progressive SNHL and neurodevelopmental delay [18, 53, 55]. Of the 
infants who are asymptomatic at birth, around 15% will later develop SNHL [18]. 
Imaging of the fetal brain can be completed in utero via transvaginal ultrasound 
or with magnetic resonance imaging (MRI). cCMV can result in germinolytic 
cysts, lenticulostriate vasculopathy, temporal lobe and occipital cysts as well as 
cerebellar hypoplasia and migrational disorders including polymicrogyria [52]. 
Periventricular calcifications is the most frequently reported finding on brain imag-
ing of cCMV cases, impacting 34–70% of diagnosed patients [56].
Testing during pregnancy is not routinely done, but serologic testing can be 
performed if a pregnant woman has been exposed or is suspected of having CMV 
infection. CMV-specific IgM has low specificity as it can persist for 6–9 month 
following primary infection and can also be detected during reactivation [54]. CMV 
IgG avidity index however can be used to confirm primary infection; avidity testing 
is a method to measure the strength of the bonding between antibodies and the 
virus. Low avidity would indicate recent infection while high avidity takes time to 
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occur and would indicate a past infection. There is no current recommended treat-
ment for acute CMV infection during pregnancy [18, 54].
There is also no current routine testing for CMV in infants. Some states have 
mandated targeted CMV screening for those who fail their routine newborn hear-
ing screen, however it is important to note that targeted screening will miss those 
newborns who are asymptomatic at birth but still at risk for developing SNHL later 
in life [18]. For symptomatic infants, the diagnosis of cCMV can be made postna-
tally if testing is done within 3 weeks of birth as to avoid the difficulty of differenti-
ating between intrauterine and perinatal infection [18, 54, 57]. CMV can be isolated 
from the urine, saliva, respiratory secretions, blood, or cerebrospinal fluid [18]. 
Viral cultures, rapid shell vial cultures, and PCR can be completed [54]. Treatment 
for those infants who are symptomatic regardless of CNS involvement includes 
intravenous ganciclovir or oral valganciclovir [18, 54, 58]. The latter is preferred due 
to ease of administration as duration of treatment is six months. If there are con-
cerns for abnormal gastrointestinal absorption due to other factors, treatment can 
be started with IV ganciclovir [54]. Studies have found that those who have anti-
viral treatment started within the first month of life have significantly improved 
audiologic and neurodevelopmental outcomes at 12 and 24 months of age compared 
to those who do not [53]. Treatment with either valganciclovir or ganciclovir can 
cause significant neutropenia; absolute neutrophil counts should be monitored 
weekly for the first six weeks of treatment, followed by screening at eight weeks of 
treatment, and thereafter monthly for the duration of treatment [54]. Infants with 
mild symptoms or isolated SNHL are not recommended to receive antiviral treat-
ment at this time due to lack of data in this population [54].
Long term outcomes to consider in children with cCMV include SNHL and 
neurodevelopmental delay. These children should have frequent audiologic assess-
ments as SNHL can develop and/or progress after the newborn period [54]. While 
there are no established universal guidelines for hearing evaluation, studies indicate 
that screening should continue for at least the first four years of life after which 
late-onset SNHL is seldom seen.
3.5 Herpes simplex virus
Herpes simplex viruses are large, double-stranded DNA viruses with two types, 
HSV-1 and HSV-2 [18]. Traditionally, HSV-1 can cause vesicular lesions in areas 
above the waist while HSV-2 involves areas below the waist. It is, however, becom-
ing increasingly more common to see genital HSV-1 lesions. Both types are able to 
cause herpetic disease in neonates when acquired from the mother. Transmission 
can occur during the birthing process via contact with genital lesions, an ascend-
ing infection, intrauterine, or postnatally from contact with lesions [18, 52]. A 
primary genital HSV infection in the mother near delivery has 10–30 times the 
risk of transmission compared to a recurrent infection. This is thought to be due 
to lower concentrations of transplacental HSV antibodies in the neonate [18, 59]. 
Unfortunately, defining an infection as primary versus recurrent may not be 
straightforward, as women can be asymptomatic and may be unaware that they 
have had a prior infection with HSV. Furthermore, viral shedding can occur in the 
absence of clinical symptoms [59].
If a pregnant woman does have genital lesions characteristic of HSV near deliv-
ery, then swabs of the lesions can be sent for viral culture and PCR with serologic 
testing to determine the type. From these results, women can be classified into four 
different categories: documented first primary infection, documented first episode 
non-primary infection, assumed first episode (primary or non-primary), or recur-
rent infection (see Table 1 adapted from Kimberlin et al.).
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Women classified as having a primary infection or first episode can be treated 
with oral acyclovir for 7–10 days [18]. Those with a recurrent episode can be treated 
with the same or higher dose for 5 days [18]. If a woman has a known history of 
HSV then suppressive therapy should be started at 36 weeks’ gestation to decrease 
the risk of recurrence at delivery, although this will not entirely suppress shedding 
[60]. Other preventative methods include avoiding invasive fetal monitoring, such 
as fetal scalp electrodes, and opting for elective cesarean sections when lesions are 
present at the time of delivery [52, 60].
Neonatal HSV can have different manifestations. SEM disease includes disease 
of the skin, eyes and/or mouth; 45% of infants with HSV will have SEM. Another 
30% of infants with HSV will have localized central nervous system (CNS) disease 
with or without skin involvement. The remaining 25% of infants with HSV will 
have disseminated disease which can involve multiple organs, most commonly the 
liver and lungs [18]. The onset of disease varies between the different manifesta-
tions, with SEM disease presenting at 5–11 days of life, CNS disease presenting 
between 8 and 17 days of life, and disseminated disease presenting between 10 
and 12 days of life [61]. Initial symptoms may be non-specific and include feed-
ing  difficulties, lethargy, seizures, suspected sepsis, vesicular rash or severe liver 
dysfunction, with as many as 30% of infected neonates not having skin lesions 
[52, 60]. As there can be high morbidity and mortality rates in newborns with HSV, 
it is imperative to diagnose and initiate treatment as soon as it is suspected [18].
Guidelines have been published on the management of asymptomatic neonates 
born to women with active genital lesions [59]. In newborns whose mothers have a 
history of genital HSV prior to pregnancy and present with active lesions at deliv-
ery, there is a low risk of transmission. However, the infant should still have surface 
swabs of the mouth, nasopharynx, conjunctivae, and anus obtained for culture and 
PCR as well as serum HSV PCR sent at 24 h of life. Waiting to send samples until 24 
h of life ensures that any positive results would represent active viral replication in 
the infant and not maternal contamination [59]. Intravenous acyclovir is not started 
in this situation unless the infant becomes symptomatic, or the surface swabs and/
or serum are positive. This would confirm infection and require a lumbar puncture 
to obtain cerebrospinal fluid (CSF) for PCR testing. The result of the CSF PCR is 
key in determining treatment duration. If the CSF and serum HSV PCR are nega-
tive, then empiric IV acyclovir is administered for a total of 10 days to prevent pro-
gression from infection to disease. If the CSF PCR is positive, then treatment should 
Table 1. 
Diagnostic tests for Herpes simplex virus (HSV) Antibodies and Culture/PCR. This table describes the 
classification of HSV infection based on culture or PCR test results as well as HSV-1 and HSV-2 antibody test 
results.
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be administered for 21 days [59]. After the treatment course has completed, a repeat 
lumbar puncture is necessary in cases of CNS disease to document clearance. If the 
repeat CSF HSV PCR is still positive, then acyclovir is continued for another 7 days. 
A repeat lumbar puncture is obtained to show clearance. This process is repeated 
until the CSF is negative. Any infant who undergoes a treatment course for HSV 
disease should have suppressive therapy with oral acyclovir for 6 months after the 
completion of parenteral treatment (see Figures 1 and 2) [59, 62].
Figure 1. 
Infant evaluation in suspected exposure to Herpes simplex virus (HSV). This flow diagram, adapted from Ref. 
[59], describes the infant evaluation(s) to complete if there was concern for maternal HSV infection around the 
time of delivery due to the presence of lesions.
Figure 2. 
Infant treatment recommendations for suspected congenital Herpes simplex virus (HSV) infection. Tis flow 
diagram, adapted from Ref. [59], describes treatment regimens based on infant symptoms.
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In the case that an asymptomatic neonate is born to a mother with active genital 
lesions but does not have a history of genital HSV prior to pregnancy, then the 
importance lies in distinguishing whether it is a primary, non-primary or recurrent 
infection [59]. The mother should not only have the swabs sent for PCR testing 
and culture but should also have serum serological tests performed for HSV-1 and 
HSV-2 antibodies. The infant requires evaluation at 24 h of life with HSV surface 
cultures and PCR testing of the serum and CSF. The CSF samples should also be 
sent for cell count and chemistries, with screening serum alanine aminotransferase 
obtained. IV acyclovir would be started empirically after obtaining the samples at 
24 h of age while awaiting results. Once the maternal testing is resulted, maternal 
classification can then be determined as shown in Table 1. If the mother is deemed 
to have a first episode primary or non-primary infection, then treatment of the 
infant would include 10 days of IV acyclovir for a normal evaluation (infant 
remains asymptomatic, negative CSF and serum HSV PCR, normal CSF indices, 
and normal serum ALT), 14 days for an abnormal evaluation (positive serum HSV 
PCR, symptomatic infant, or abnormal ALT) and 21 days for CNS infection (posi-
tive CSF PCR or abnormal indices) [59]. A neonate with a positive CSF HSV PCR, 
regardless of the maternal classification, would be managed as described above 
for HSV disease. It is important to note that if the infant becomes symptomatic at 
any point, even prior to the testing obtained at 24 h of life, then immediate evalu-
ation and treatment should be initiated [59]. Other risk factors that may prompt 
testing and treatment prior the 24 h include: prolonged rupture of membranes 
(>4–6 h) and prematurity (<37 weeks’ gestation) in the setting of maternal genital 
lesions characteristic of HSV [59].
Only 10% of infants survive in untreated HSV disseminated disease with 50% 
of infants surviving in untreated HSV CNS disease [61]. Inadequately treated 
or untreated HSV SEM disease can progress to either disseminated or CNS dis-
ease; those that survive have a significant proportion that show some neurologic 
sequelae, namely in the form of motor, speech, and developmental delay [61]. 
Outcomes, especially mortality, improve the earlier that treatment is initiated, mak-
ing it imperative to evaluate and begin empiric treatment whenever HSV infection 
is suspected [61]. Oral suppressive therapy has also been shown to improve neuro-
developmental outcomes at 12 months of age compared to those that did not receive 
long-term antivirals, suggesting that ongoing neurologic injury may occur in infants 
affected by HSV disease [62].
4. Additional viruses
A review of additional viruses that can impact infants exposed during preg-
nancy is provided below. These viruses have been associated with a range of adverse 
outcomes in infants with prenatal/perinatal exposure, however they remain uncom-
monly diagnosed or the impact on the fetus remains extremely varied. However, 
given the increased risk of potential adverse outcomes, they are briefly discussed.
4.1 Hepatitis E
The hepatitis E virus (HEV) is a single-stranded RNA virus which is known as 
a major cause of acute viral hepatitis especially in developing countries through 
ingestion of contaminated water sources [18, 63]. While it generally causes a mild 
illness in most adults, pregnant women tend to have more severe disease. Mortality 
has been observed in pregnant women, especially if infected with genotype 1 
[18, 63]. HEV is estimated to be responsible for up to 3000 stillbirths a year in 
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developing countries and can commonly cause preterm delivery in infected mothers 
with resultant poor neonatal outcomes [63, 64]. When HEV is transmitted verti-
cally, hepatitis can be present from birth and persist throughout the infant’s life but 
is not known to be associated with congenital anomalies.
4.2 Enterovirus
Enteroviruses are a group of RNA viruses that can spread between humans via 
respiratory routes, vertically, and fecal-oral transmission [18]. Symptoms in adults 
and children can be varied and may include respiratory, dermatologic, neurologic, 
ocular, cardiac, muscular, and gastrointestinal manifestations [18]. When entero-
virus is transmitted vertically or more commonly peripartum, the neonate may 
remain asymptomatic without sequelae or have severe symptoms including septic 
shock with multiorgan dysfunction [65]. There is limited evidence to suggest that 
infection with enterovirus during pregnancy is associated with congenital anoma-
lies or fetal death [65].
4.3 Congenital lymphocytic choriomeningitis virus syndrome
Lymphocytic choriomeningitis virus (LCMV) is a single-stranded RNA virus 
spread by rodents which can cross the placenta; rarely it can be transmitted during 
delivery by exposure to maternal secretions or blood and cause congenital viral 
infection [66–68]. Infected pregnant women can have non-specific viral symp-
toms and may report direct exposure to or the presence of rodents in their homes 
[66, 68]. Common findings in an infant affected by LCMV are macrocephaly or 
microcephaly and ocular abnormalities; additionally, neurological abnormali-
ties may be present and include hydrocephalus, periventricular calcifications, 
seizures, neurodevelopmental sequelae including intellectual disability, or even 
death [67, 68]. These symptoms suggest a similarity with other congenital infec-
tions previously discussed, such as CMV or toxoplasmosis, which may contribute 
to an underestimation of the prevalence of LCMV when congenital infection is 
suspected [66, 68].
4.4 West Nile Virus
The West Nile Virus (WNV) is a flavivirus that was initially isolated in 1937 
and did not reach the United States until an outbreak in 1999 [69–71]. The primary 
mode of transmission is through the bite of an infected Culex species mosquito, 
with individuals ranging from no symptoms to 0.7% of infected individuals devel-
oping neuro-invasive disease with encephalitis, meningitis or acute flaccid paralysis 
possible [69]. There is no specific treatment or vaccine at this time [70]. Case 
reports of infants born to mothers with WNV have shown an array of outcomes, 
with follow up at 2–3 years of age not consistently showing any developmental 
delays [69]. Findings have included chorioretinitis, white-matter loss and cystic 
changes, and congenital defects such as lissencephaly, polydactyly, aortic coarcta-
tion and cleft palate [69]. Additional studies on the impact of infants with exposure 
during gestation, and longer-term outcomes are needed to truly delineate if WNV 
results in congenital anomalies.
4.5 Adenovirus
Human adenoviruses (HAdV) are DNA viruses in the Adenoviridae family, with 
7 subgroups and 52 serotypes [72]. While typically the cause of a “cold”, the severity 
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of illness can range from mild to severe with gastroenteritis, pneumonia and 
neurologic disease possible [73]. Reports have not noted any specific fetal malfor-
mations, although infants with positive polymerase chain reaction (PCR) testing 
had a higher incidence of neural tube defects and echogenic liver lesions with and 
without hydrops [74].
5. Conclusion
Many of the maternal infections that previously resulted in significant impact 
and poor outcomes on the developing fetus have improved as treatments and vac-
cines have been introduced and refined. However, other pathogens are now becom-
ing more apparent in their impact on fetal development, such as Zika virus. Some 
infections are declining in incidence, with a resultant decrease in congenital infec-
tions (such as the nearly 80% decline in Rubella infections) [51]. Other infections 
are continuing to increase, with the true impact on society yet to be determined. 
Thus, it is imperative that we monitor any infections in a pregnant woman, and 
complete a thorough examination and evaluation of each infant born with the hopes 
of identifying any abnormalities quickly and improving the outcomes of each infant 
to the best of our ability.
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